🇫🇷 IPN.PA — Ipsen S.A.

Salud Mantener
← Volver

Precio actual

153,20 EUR

Máx. histórico

172,90

181 días

Caída desde máximo

-11,39%

Rango 52 semanas

115,60 – 174,00

Variación hoy

-1,42%

Cierre anterior

155,40

Rango de hoy

152,70 – 157,00

Volumen hoy

131.211

Peor caída histórica

-75,62%

30/08/2018 → 18/03/2020

Recuperado en 2157 días

Volatilidad anualizada ⓘ

30,51%

Información
Nombre completo
Ipsen S.A.
Divisa
EUR
Mercado
Paris
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
5.535
PER ⓘ
24,79 (puede no estar actualizado)
Dividend yield
1,03% (puede no estar actualizado)
Precio objetivo analistas
161,92 EUR (puede no estar actualizado)
Primera cotización
07/12/2005
Precio actualizado
hace 6 horas
Sobre la empresa

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Dividendos repartidos Total últimos 12 meses: 1,6000 EUR · Yield: 1,04%
Fecha de pago Importe por participación
03/06/2026 1,6000 EUR
04/06/2025 1,4000 EUR
30/05/2024 1,2000 EUR
02/06/2023 1,2000 EUR
31/05/2022 1,2000 EUR
31/05/2021 1,0000 EUR
03/06/2020 1,0000 EUR
31/05/2019 1,0000 EUR
04/06/2018 1,0000 EUR
09/06/2017 0,8500 EUR
02/06/2016 0,8500 EUR
29/05/2015 0,8500 EUR
09/06/2014 0,8000 EUR
05/06/2013 0,8000 EUR
06/06/2012 0,8000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/01/2006 25,95 25,95 25,40 25,50 -0,74% 2,12% 10.226
27/01/2006 25,90 25,90 25,52 25,69 +0,35% 1,47% 19.100
26/01/2006 25,85 26,00 25,60 25,60 -1,50% 1,55% 15.148
25/01/2006 25,70 25,99 25,65 25,99 +0,04% 1,32% 12.112
24/01/2006 25,90 25,99 25,41 25,98 +2,28% 2,24% 40.534
23/01/2006 25,00 25,40 24,45 25,40 +0,99% 3,80% 34.576
20/01/2006 25,79 26,00 25,01 25,15 -3,45% 3,84% 43.721
19/01/2006 26,50 26,60 26,05 26,05 -1,33% 2,08% 28.488
18/01/2006 26,75 26,75 25,01 26,40 -1,12% 6,50% 87.618
17/01/2006 26,90 26,90 26,60 26,70 -0,19% 1,12% 23.892
16/01/2006 27,00 27,00 26,75 26,75 -0,93% 0,93% 38.716
13/01/2006 26,68 27,00 26,60 27,00 +1,96% 1,50% 17.276
12/01/2006 26,50 26,55 26,27 26,48 +1,26% 1,06% 65.594
11/01/2006 26,15 26,20 26,01 26,15 -0,19% 0,73% 27.057
10/01/2006 26,48 26,48 26,10 26,20 -0,72% 1,44% 146.573
09/01/2006 26,00 26,50 26,00 26,39 +2,49% 1,92% 177.849
06/01/2006 24,55 25,75 24,50 25,75 +4,97% 5,09% 175.916
05/01/2006 24,00 24,53 23,75 24,53 +2,21% 3,25% 51.703
04/01/2006 23,80 24,25 23,52 24,00 +0,84% 3,07% 23.786
03/01/2006 23,95 23,95 23,77 23,80 -0,38% 0,75% 17.664
02/01/2006 24,00 24,05 23,89 23,89 -0,13% 0,67% 16.612
30/12/2005 24,05 24,05 23,70 23,92 -0,33% 1,46% 36.485
29/12/2005 23,95 24,05 23,78 24,00 +0,00% 1,13% 19.343
28/12/2005 23,85 24,06 23,85 24,00 -0,25% 0,88% 11.087
27/12/2005 24,14 24,35 24,00 24,06 -0,17% 1,45% 34.663
26/12/2005 24,10 24,10 24,10 24,10 +0,00% 0,00% 0
23/12/2005 23,50 24,22 23,50 24,10 +1,26% 3,06% 31.384
22/12/2005 23,90 24,00 23,80 23,80 -0,38% 0,84% 40.258
21/12/2005 23,55 23,90 23,55 23,89 +0,59% 1,49% 22.194
20/12/2005 23,89 23,89 23,30 23,75 -0,63% 2,47% 28.896